You are here

  • Home
  • Archive
  • Volume 12, Issue 7
  • Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers

 

Online download statistics by month:

Online download statistics by month: July 2024 to January 2026

AbstractFullPdf
Jul 202433633795
Aug 2024207206100
Sep 202411411259
Oct 202410710778
Nov 2024969765
Dec 2024959664
Jan 202512712787
Feb 202522422472
Mar 2025808163
Apr 202513013066
May 2025848560
Jun 2025535335
Jul 2025110
Jan 2026110
Total16551657844